關鍵趨勢
影響2023年全球醫藥市場的主要因素包括:中國大陸對於生物製劑需求增加、生物相似性藥品興起、個人化藥物研發取得進展，以及聯合國永續發展目標中的重點疾病治療
| Drug Name | Company | Therapy Area | Year |
|
Faricimab |
Roche and Chugai Pharmaceutical | Diabetic macular edema and wet age-related macular degeneration | 2022 |
|
Adagrasib |
Mirati Therapeutics, Zai Lab Limited | KRASG12C-positive NSCLC and CRC | 2022 |
|
Vutrisiran |
Alnylam Pharmaceuticals Inc. | Transthyretin-mediated amyloidosis-related polyneuropathy | 2022 |
|
Tirzepatide |
Eli Lilly and Co. | Type 2 diabetes mellitus | 2022 |
|
Tezepelumab |
Amgen, AstraZeneca plc | Severe asthma | 2022 |
|
Donanemab |
Eli Lilly and Co. | 阿茲海默症 | 2022 |
|
Lecanemab |
Biogen Inc., Esai Co Ltd. | 阿茲海默症 | 2022 |
|
Aducanumab
|
Biogen Inc., Esai Co Ltd. | Neurology/psychiatric - Alzheimer’s disease | 2021 |
|
Bimekizumab
|
UCB | Excessive immune response/autoimmunity - psoriasis | 2021 |
|
Relugolix
|
ASKA Pharmaceutical Co. Ltd., Gedeon Richter, Myovant Sciences Ltd, Pfizer Inc., Takeda Pharmaceutical Co. Ltd. | Oncology - prostate cancer, Reproductive health - endometriosis & uterine fibroids | 2021 |
|
Vericiguat
|
Bayer AG, Merck & Co. | Cardiovascular – heart failure | 2021 |
|
Filgotinib (GLPG-0634) |
Galapagos NV, Gilead Sciences Inc. | Excessive immune response/autoimmunity | 2020 |
|
Inclisiran (ALN-PCSsc; ALN-60212; PCSK9si; Leqvio) |
The Medicines Co. | Cardiovascular disease | 2020 |
|
Lisocabtagene maraleucel (JCAR-017; Liso-cel) |
Celgene Corporation | Oncology | 2020 |
|
Ofatumumab (OMB-157; Kesimpta) |
Novartis International AG | Neurology/psychiatric | 2020 |
|
Ozanimod (RPC-1063; Zeposia) |
Celgene Corporation | Neurology/psychiatric | 2020 |
|
Rimegepant (BHV-3000; Nurtec) |
Biohaven Pharmaceutical Holding Co. Ltd. | Neurology/psychiatric | 2020 |
|
Sacituzumab govitecan (IMMU-132) |
Immunomedics Inc., Medicine Inc. | Oncology | 2020 |
|
Semaglutide (Rybelsus) |
Novo Nordisk A/S | Endocrinology/metabolic disease | 2020 |
|
Trastuzumab deruxtecan (DS-8201a; Enhertu) |
AstraZeneca plc, Daiichi Sankyo Co. Ltd. | Oncology | 2020 |
|
Vadadustat |
Akebia Therapeutics Inc., Mitsubishi Tanabe Pharma America Inc., Otsuka Pharmaceutical | Chronic disease complication | 2020 |
|
Valoctocogene roxaparvovec (BMN-270; Valrox) |
Biomarin Pharmaceutical Inc. | Genetic disorder | 2020 |
|
Betibeglogene darolentivec (LentiGlobin) |
Bluebird Bio Inc. | Genetic disorder | 2019 |
|
Onasemnogene abeparvovec (AVXS-101; Zolgensma) |
AveXis | Genetic disorder | 2019 |
|
Palforzia (AR101; Aerumab) |
Aimmune Therapeutics | Excessive immune response/autoimmunity | 2019 |
影響2023年全球醫藥市場的主要因素包括:中國大陸對於生物製劑需求增加、生物相似性藥品興起、個人化藥物研發取得進展，以及聯合國永續發展目標中的重點疾病治療
